CHANGE OF NAME

Cellbxhealth

29/10/2025 07:00

RNS Number : 1968F

Cellbxhealth PLC

29 October 2025

 

29 October 2025

 

ANGLE plc ("the Company")

 

Change of Name

 

Further to the announcement on 8 October 2025, ANGLE plc announces that the application to change the name of the Company to CelLBxHealth plc has now been registered at Companies House.

 

Accordingly, the Company's change of name and change of TIDM to CLBX will be effective on the London Stock Exchange plc from 8.00 a.m. on 29 October 2025. The Company's ISIN and SEDOL remain unchanged.

 

In conjunction with the name change, the Company's website address will change to CelLBxHealth.com. All information required by AIM Rule 26 will be located on the "Investors" section of the angleplc.com website with effect from 8.00 a.m. on 29 October 2025.

 

Shareholders' rights are unaffected by the change and existing share certificates should be retained and remain valid.

 

For further information:

 

CelLBxHealth
+44 (0) 1483 343434
Dr Jan Groen, Executive Chairman
Peter Collins, Interim CEO
investor@cellbxhealth.com
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper/ Hamza Munshi (Corporate Finance)
Sunila de Silva (Corporate Broking)
Nigel Birks (Life Science Specialist Sales)
+44 (0) 20 7220 0500
FTI Consulting
Simon Conway, Ciara Martin, Sam Purewal
Matthew Ventimiglia (US)
+44 (0) 203 727 1000
+1 (212) 850 5624

 

Notes for editors

 

About CelLBxHealth plc

 

CelLBxHealth plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis including whole-cell imaging, proteomic profiling and full genomic workflows.

 

Commercial activities focus on (1) Product Sales:  Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme (3) Laboratory services: Clinical trial support and assay development.

 

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from the Company's GLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAMPBMTMTMTTJA